Yvonne Greenstreet, CEO & Director of Alnylam Pharmaceuticals, sold company shares.
2 reports, 1 independent
Updated Aug 11
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Yvonne Greenstreet, CEO & Director of Alnylam Pharmaceuticals, sold company shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Yvonne Greenstreet
British biotechnology executive
Nothing else this week.
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
Coverage
Newest first; wire copies grouped- Simply Wall St.Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock Many Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insiders ditched their stock over the past year, which may be of intere
- Unknown outlet